Uncategorized

The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a continued appetite for these drugs.

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals after-the-fact rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.

Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate zetomipzomib faces a partial clinical hold barring four trial participants from continuing treatment in the open-label portion of the trial, though the trial itself will continue as planned.

Leerink analysts said the results were largely in line with outcomes in a trial of Inspire Medical’s rival device but cautioned that Livanova may have a hard time breaking into the sleep apnea market.

Medical groups’ median investment per employed physician reached $304,312 in the third quarter, the first time the metric has risen above $300,000, according to Kaufman Hall.

A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year.

The acquisition will give BioNTech full ownership of an investigational bispecific antibody targeting the PD-L1/VEGF-A pathways, a hot area in oncology that could potentially replace standard checkpoint inhibitors for cancer treatment.

Cantor Fitzgerald analyst Olivia Brayer found supplementary bone marrow density data for Amgen’s obesity candidate MariTide which could point to a potentially greater fracture risk than previously revealed, but some other analysts view the findings as a nonissue.

The plan requires only copays for medical services and prescription drugs up to the plan member’s out-of-pocket maximum, with no deductibles or coinsurance costs.